Komori
Share Issuance and Disposal4563AnGes,Inc.Pharmaceuticals

Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Adjustment Provisions

In April 2026, 8,000 Series 46 stock acquisition rights with exercise price adjustment clauses were exercised, and 800,000 new shares were issued. The number of outstanding unexercised rights at month-end was 854,171.

Worth reading
55In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
800000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Exercise status report for stock acquisition rights with exercise price adjustment clauses (Series 46 stock acquisition rights)

発行・処分する株式数

800,000 new shares (0 treasury shares transferred)

発行済株式総数

Approximately 0.20% (800,000 shares ÷ 396,334,550 issued shares as of the end of the month preceding the target month)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
The exercise price in April 2026 was ¥45.9–¥54.0. Details of the adjustment clause and the floor: Not disclosed
Number of Stock Acquisition Rights
Total issued: 960,000 rights; exercised during the target month: 8,000 rights; unexercised at the end of the target month: 854,171 rights
Procedures under the Corporate Code of Conduct
The disclosure describes the compliance status regarding exercise restrictions under Article 434 of the Tokyo Stock Exchange Securities Listing Regulations and the rules of the Japan Securities Dealers Association.
Most recent equity financing
Timing Issued on 25 November 2025 / Type Series 46 stock acquisition rights with exercise price adjustment clauses / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalExercise status report for stock acquisition rights with exercise price adjustment clauses (Series 46 stock acquisition rights)
Number of shares to be issued or disposed of800,000 new shares (0 treasury shares transferred)
Dilution RateApproximately 0.20% (800,000 shares ÷ 396,334,550 issued shares as of the end of the month preceding the target month)
Total number of issued shares396,334,550 shares (as of the end of the month preceding the target month) → Not disclosed
Exercise priceThe exercise price in April 2026 was ¥45.9–¥54.0. Details of the adjustment clause and the floor: Not disclosed
Number of Stock Acquisition RightsTotal issued: 960,000 rights; exercised during the target month: 8,000 rights; unexercised at the end of the target month: 854,171 rights
Procedures under the Corporate Code of ConductThe disclosure describes the compliance status regarding exercise restrictions under Article 434 of the Tokyo Stock Exchange Securities Listing Regulations and the rules of the Japan Securities Dealers Association.
Most recent equity financingTiming Issued on 25 November 2025 / Type Series 46 stock acquisition rights with exercise price adjustment clauses / Amount Not disclosed
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status of the Series 46 stock acquisition rights with exercise price adjustment clauses for April 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Adjustment Provisions | AnGes,Inc. (4563) timely disclosure | Komori